FibroGen Inc (FGEN) Position Trimmed by Eagle Asset Management Inc.

Eagle Asset Management Inc. trimmed its position in shares of FibroGen Inc (NASDAQ:FGEN) by 1.3% in the fourth quarter, HoldingsChannel reports. The firm owned 818,865 shares of the biopharmaceutical company’s stock after selling 10,573 shares during the period. Eagle Asset Management Inc.’s holdings in FibroGen were worth $39,034,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can grew its holdings in FibroGen by 2,097.2% during the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 3,041 shares in the last quarter. Fortaleza Asset Management Inc. grew its holdings in FibroGen by 95.0% during the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after acquiring an additional 1,700 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in FibroGen by 41.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 1,147 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares in the last quarter. 56.78% of the stock is owned by institutional investors and hedge funds.

FibroGen Inc (NASDAQ:FGEN) opened at $56.50 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen Inc has a fifty-two week low of $22.75 and a fifty-two week high of $63.00.

In other news, CEO Thomas B. Neff sold 18,900 shares of the firm’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $42.71, for a total value of $807,219.00. Following the transaction, the chief executive officer now directly owns 3,060,887 shares in the company, valued at approximately $130,730,483.77. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.66, for a total transaction of $1,725,483.76. Following the completion of the transaction, the chief executive officer now owns 3,022,934 shares in the company, valued at $135,004,232.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 353,017 shares of company stock valued at $17,863,586. 13.60% of the stock is owned by company insiders.

Several research analysts have weighed in on the stock. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Mizuho reissued a “hold” rating and set a $61.00 price objective on shares of FibroGen in a report on Thursday, November 9th. Finally, BidaskClub lowered shares of FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Four research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $65.67.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/02/18/fibrogen-inc-fgen-position-trimmed-by-eagle-asset-management-inc.html.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply